These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 12544490)
21. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Buchlis G; Podsakoff GM; Radu A; Hawk SM; Flake AW; Mingozzi F; High KA Blood; 2012 Mar; 119(13):3038-41. PubMed ID: 22271447 [TBL] [Abstract][Full Text] [Related]
22. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Herzog RW; Yang EY; Couto LB; Hagstrom JN; Elwell D; Fields PA; Burton M; Bellinger DA; Read MS; Brinkhous KM; Podsakoff GM; Nichols TC; Kurtzman GJ; High KA Nat Med; 1999 Jan; 5(1):56-63. PubMed ID: 9883840 [TBL] [Abstract][Full Text] [Related]
23. Persistent expression of canine factor IX in hemophilia B canines. Chao H; Samulski R; Bellinger D; Monahan P; Nichols T; Walsh C Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718 [TBL] [Abstract][Full Text] [Related]
25. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Nakai H; Herzog RW; Hagstrom JN; Walter J; Kung SH; Yang EY; Tai SJ; Iwaki Y; Kurtzman GJ; Fisher KJ; Colosi P; Couto LB; High KA Blood; 1998 Jun; 91(12):4600-7. PubMed ID: 9616156 [TBL] [Abstract][Full Text] [Related]
26. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Manno CS; Pierce GF; Arruda VR; Glader B; Ragni M; Rasko JJ; Ozelo MC; Hoots K; Blatt P; Konkle B; Dake M; Kaye R; Razavi M; Zajko A; Zehnder J; Rustagi PK; Nakai H; Chew A; Leonard D; Wright JF; Lessard RR; Sommer JM; Tigges M; Sabatino D; Luk A; Jiang H; Mingozzi F; Couto L; Ertl HC; High KA; Kay MA Nat Med; 2006 Mar; 12(3):342-7. PubMed ID: 16474400 [TBL] [Abstract][Full Text] [Related]
27. Muscle as a target for supplementary factor IX gene transfer. Hoffman BE; Dobrzynski E; Wang L; Hirao L; Mingozzi F; Cao O; Herzog RW Hum Gene Ther; 2007 Jul; 18(7):603-13. PubMed ID: 17594244 [TBL] [Abstract][Full Text] [Related]
30. Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Monahan PE; Lothrop CD; Sun J; Hirsch ML; Kafri T; Kantor B; Sarkar R; Tillson DM; Elia JR; Samulski RJ Mol Ther; 2010 Nov; 18(11):1907-16. PubMed ID: 20700109 [TBL] [Abstract][Full Text] [Related]
31. Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B. George LA; Ragni MV; Rasko JEJ; Raffini LJ; Samelson-Jones BJ; Ozelo M; Hazbon M; Runowski AR; Wellman JA; Wachtel K; Chen Y; Anguela XM; Kuranda K; Mingozzi F; High KA Mol Ther; 2020 Sep; 28(9):2073-2082. PubMed ID: 32559433 [TBL] [Abstract][Full Text] [Related]
32. Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Arruda VR; Stedman HH; Nichols TC; Haskins ME; Nicholson M; Herzog RW; Couto LB; High KA Blood; 2005 May; 105(9):3458-64. PubMed ID: 15479726 [TBL] [Abstract][Full Text] [Related]
35. Parvovirus-mediated gene transfer for the haemophilias. Walsh CE; Chao H Haemophilia; 2002 Mar; 8 Suppl 2():60-7. PubMed ID: 11966856 [TBL] [Abstract][Full Text] [Related]
36. New and improved AAVenues: current status of hemophilia B gene therapy. Brimble MA; Reiss UM; Nathwani AC; Davidoff AM Expert Opin Biol Ther; 2016; 16(1):79-92. PubMed ID: 26524468 [TBL] [Abstract][Full Text] [Related]
37. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Arruda VR; Stedman HH; Haurigot V; Buchlis G; Baila S; Favaro P; Chen Y; Franck HG; Zhou S; Wright JF; Couto LB; Jiang H; Pierce GF; Bellinger DA; Mingozzi F; Nichols TC; High KA Blood; 2010 Jun; 115(23):4678-88. PubMed ID: 20335222 [TBL] [Abstract][Full Text] [Related]
38. Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients? High K J Thromb Haemost; 2005 Aug; 3(8):1682-91. PubMed ID: 16102034 [TBL] [Abstract][Full Text] [Related]
39. Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer. Cooper M; Nayak S; Hoffman BE; Terhorst C; Cao O; Herzog RW Hum Gene Ther; 2009 Jul; 20(7):767-76. PubMed ID: 19309290 [TBL] [Abstract][Full Text] [Related]
40. Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs. Haurigot V; Mingozzi F; Buchlis G; Hui DJ; Chen Y; Basner-Tschakarjan E; Arruda VR; Radu A; Franck HG; Wright JF; Zhou S; Stedman HH; Bellinger DA; Nichols TC; High KA Mol Ther; 2010 Jul; 18(7):1318-29. PubMed ID: 20424599 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]